Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733265 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00733265 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT00733265, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
Interventions
- DRUG AZD6140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733265
The ClinicalTrials.gov registry entry for NCT00733265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD6140 is the first listed.
NCT00733265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733265 about?
NCT00733265 is a clinical study titled "Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers". The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
What is the current status of trial NCT00733265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00733265?
The interventions under investigation include: AZD6140 (DRUG).
Who is sponsoring clinical trial NCT00733265?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.